Suppr超能文献

基于结构对接识别新型Smoothened配体

Identification of Novel Smoothened Ligands Using Structure-Based Docking.

作者信息

Lacroix Celine, Fish Inbar, Torosyan Hayarpi, Parathaman Pranavan, Irwin John J, Shoichet Brian K, Angers Stephane

机构信息

Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, United States of America.

出版信息

PLoS One. 2016 Aug 4;11(8):e0160365. doi: 10.1371/journal.pone.0160365. eCollection 2016.

Abstract

The seven transmembrane protein Smoothened is required for Hedgehog signaling during embryonic development and adult tissue homeostasis. Inappropriate activation of the Hedgehog signalling pathway leads to cancers such as basal cell carcinoma and medulloblastoma, and Smoothened inhibitors are now available clinically to treat these diseases. However, resistance to these inhibitors rapidly develops thereby limiting their efficacy. The determination of Smoothened crystal structures enables structure-based discovery of new ligands with new chemotypes that will be critical to combat resistance. In this study, we docked 3.2 million available, lead-like molecules against Smoothened, looking for those with high physical complementarity to its structure; this represents the first such campaign against the class Frizzled G-protein coupled receptor family. Twenty-one high-ranking compounds were selected for experimental testing, and four, representing three different chemotypes, were identified to antagonize Smoothened with IC50 values better than 50 μM. A screen for analogs revealed another six molecules, with IC50 values in the low micromolar range. Importantly, one of the most active of the new antagonists continued to be efficacious at the D473H mutant of Smoothened, which confers clinical resistance to the antagonist vismodegib in cancer treatment.

摘要

七次跨膜蛋白Smoothened在胚胎发育和成年组织稳态过程中的Hedgehog信号传导中是必需的。Hedgehog信号通路的不适当激活会导致基底细胞癌和髓母细胞瘤等癌症,目前临床上已有Smoothened抑制剂用于治疗这些疾病。然而,对这些抑制剂的耐药性迅速产生,从而限制了它们的疗效。确定Smoothened的晶体结构能够基于结构发现具有新化学类型的新配体,这对于对抗耐药性至关重要。在本研究中,我们将320万个可用的类先导分子与Smoothened进行对接,寻找与其结构具有高度物理互补性的分子;这是针对卷曲蛋白G蛋白偶联受体家族的首次此类研究。选择了21种排名靠前的化合物进行实验测试,鉴定出四种代表三种不同化学类型的化合物,它们以优于50μM的IC50值拮抗Smoothened。对类似物的筛选又发现了另外六种分子,其IC50值在低微摩尔范围内。重要的是,新拮抗剂中活性最高的一种对Smoothened的D473H突变体仍然有效,该突变体在癌症治疗中赋予了对拮抗剂维莫德吉的临床耐药性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验